117 related articles for article (PubMed ID: 1923517)
1. Inhibition of jun transformation by a mutated fos gene: design of an anti-oncogene.
Okuno H; Suzuki T; Yoshida T; Hashimoto Y; Curran T; Iba H
Oncogene; 1991 Sep; 6(9):1491-7. PubMed ID: 1923517
[TBL] [Abstract][Full Text] [Related]
2. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos.
Morgan IM; Ransone LJ; Bos TJ; Verma IM; Vogt PK
Oncogene; 1992 Jun; 7(6):1119-25. PubMed ID: 1594243
[TBL] [Abstract][Full Text] [Related]
3. fos-jun Conspiracy: implications for the cell.
Verma IM; Ransone LJ; Visvader J; Sassone-Corsi P; Lamph WW
Princess Takamatsu Symp; 1989; 20():119-26. PubMed ID: 2518685
[TBL] [Abstract][Full Text] [Related]
4. Analysis of dimerization and DNA binding functions in Fos and Jun by domain-swapping: involvement of residues outside the leucine zipper/basic region.
Cohen DR; Curran T
Oncogene; 1990 Jun; 5(6):929-39. PubMed ID: 2113670
[TBL] [Abstract][Full Text] [Related]
5. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
[TBL] [Abstract][Full Text] [Related]
6. Changing fos oncoprotein to a jun-independent DNA binding protein with GCN4 dimerization specificity by swapping "leucine zippers".
Sellers JW; Struhl K
Nature; 1989 Sep; 341(6237):74-6. PubMed ID: 2505087
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of a dominant-negative mutant of c-Jun.
Brown PH; Chen TK; Birrer MJ
Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
[TBL] [Abstract][Full Text] [Related]
8. Heterodimerization with c-Fos is not required for cell transformation of chicken embryo fibroblasts by Jun.
Hughes M; Sehgal A; Hadman M; Bos T
Cell Growth Differ; 1992 Dec; 3(12):889-97. PubMed ID: 1472469
[TBL] [Abstract][Full Text] [Related]
9. Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription.
Blazek E; Wasmer S; Kruse U; Aronheim A; Aoki M; Vogt PK
Oncogene; 2003 Apr; 22(14):2151-9. PubMed ID: 12687017
[TBL] [Abstract][Full Text] [Related]
10. Encounters with Fos and Jun on the road to AP-1.
Abate C; Curran T
Semin Cancer Biol; 1990 Feb; 1(1):19-26. PubMed ID: 2133107
[TBL] [Abstract][Full Text] [Related]
11. Jun DNA-binding is modulated by mutations between the leucines or by direct interaction of fos with the TGACTCA sequence.
Hirai S; Yaniv M
New Biol; 1989 Nov; 1(2):181-91. PubMed ID: 2562220
[TBL] [Abstract][Full Text] [Related]
12. Addition of positively charged tripeptide to N-terminus of the Fos basic region leucine zipper domain: implications on DNA bending, affinity, and specificity.
Mahmoudi T; Sarkar B
Biopolymers; 1999 Sep; 50(3):273-86. PubMed ID: 10397789
[TBL] [Abstract][Full Text] [Related]
13. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
Bader AG; Schneider ML; Bister K; Hartl M
Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
[TBL] [Abstract][Full Text] [Related]
14. Escape from redox regulation enhances the transforming activity of Fos.
Okuno H; Akahori A; Sato H; Xanthoudakis S; Curran T; Iba H
Oncogene; 1993 Mar; 8(3):695-701. PubMed ID: 8437852
[TBL] [Abstract][Full Text] [Related]
15. Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
Brown PH; Alani R; Preis LH; Szabo E; Birrer MJ
Oncogene; 1993 Apr; 8(4):877-86. PubMed ID: 8455942
[TBL] [Abstract][Full Text] [Related]
16. Mutagenesis of the DNA contact site in Fos protein: compatibility with the scissors grip model and requirement for transformation.
Neuberg M; Schuermann M; Müller R
Oncogene; 1991 Aug; 6(8):1325-33. PubMed ID: 1909428
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Fos- and Ras-induced transformation by mutant Fos proteins with structural alterations in functionally different domains.
Wick M; Lucibello FC; Müller R
Oncogene; 1992 May; 7(5):859-67. PubMed ID: 1570155
[TBL] [Abstract][Full Text] [Related]
18. Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun.
Kerppola TK; Curran T
Oncogene; 1994 Mar; 9(3):675-84. PubMed ID: 8108109
[TBL] [Abstract][Full Text] [Related]
19. fos and jun interaction: the role of the leucine zipper.
Ransone LJ; Visvader J; Lamph WW; Sassone-Corsi P; Verma IM
Int J Cancer Suppl; 1989; 4():10-21. PubMed ID: 2509385
[TBL] [Abstract][Full Text] [Related]
20. fra-2 promoter can respond to serum-stimulation through AP-1 complexes.
Sonobe MH; Yoshida T; Murakami M; Kameda T; Iba H
Oncogene; 1995 Feb; 10(4):689-96. PubMed ID: 7862446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
